Tumor Microenvironment Remodeling Contributes to the Resistance to EGFR-TKI in EGFR-mutated Non-small Cell Lung Cancer

被引：0
|
作者：
Song, X. [1 ]
Zhou, C. [2 ]
Wu, F. [2 ]
机构：
[1] Tongji Univ, Shanghai Pulm Hosp, Sch Med, Shanghai, Peoples R China
[2] Shanghai Pulm Hosp, Shanghai, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 11期
关键词：
EGFR mutation; Tyrosine kinase inhibitor resistance; Tumor microenvironment;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2.12-01
引用
收藏
页码：S362 / S362
页数：1
相关论文
共 50 条
  • [1] Overcoming EGFR-TKI resistance in EGFR-mutated lung cancer
    Gardizi, M.
    Scheffler, M.
    Bos, M.
    Geist, T.
    Heukamp, L.
    Nogova, L.
    Toepelt, K.
    Fernandez-Cuesta, L.
    Culmann, H.
    Kaminsky, B.
    Panse, J.
    Becker, C.
    Mattonet, C.
    Serke, M.
    Schmitz, S.
    Schnell, R.
    Galetke, W.
    Hekmat, K.
    Buettner, R.
    Wolf, J.
    ONKOLOGIE, 2013, 36 : 30 - 30
  • [2] Molecular Mechanism of EGFR-TKI Resistance in EGFR-Mutated Non-Small Cell Lung Cancer: Application to Biological Diagnostic and Monitoring
    Reita, Damien
    Pabst, Lucile
    Pencreach, Erwan
    Guerin, Eric
    Dano, Laurent
    Rimelen, Valerie
    Voegeli, Anne-Claire
    Vallat, Laurent
    Mascaux, Celine
    Beau-Faller, Michele
    CANCERS, 2021, 13 (19)
  • [3] EGFR-Mutated Non-Small Cell Lung Cancer and Resistance to Immunotherapy: Role of the Tumor Microenvironment
    Madeddu, Clelia
    Donisi, Clelia
    Liscia, Nicole
    Lai, Eleonora
    Scartozzi, Mario
    Maccio, Antonio
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (12)
  • [4] Pooled safety analysis of EGFR-TKI therapy in patients with EGFR-mutated non-small cell lung cancer.
    Takada, Masayuki
    Okamoto, Isamu
    Nakagawa, Kazuhiko
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [5] Deciphering the Characterization of Tumor Microenvironment in EGFR-Mutated Non-Small Cell Lung Cancer
    Qiao, M.
    Jiang, T.
    Ren, S.
    Zhou, C.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S182 - S183
  • [6] Apatinib combined with EGFR-TKI in treating advanced non-small cell lung cancer with EGFR-TKI resistance
    Tian, R.
    Guo, W.
    Guo, Y.
    Zhang, X.
    Zhu, H.
    Shen, F.
    Xu, J.
    Zhang, X.
    Wang, R.
    Ren, X.
    Li, J.
    Song, X.
    ANNALS OF ONCOLOGY, 2019, 30
  • [7] Which is better, EGFR-TKI mono or combination for non-small cell lung cancer with mutated EGFR?
    Tanzawa, Shigeru
    Ishihara, Masashi
    Haruyama, Terunobu
    Ochiai, Ryosuke
    Sakamoto, Takahiko
    Honda, Takeshi
    Ota, Shuji
    Ichikawa, Yasuko
    Watanabe, Kiyotaka
    Seki, Nobuhiko
    TRANSLATIONAL CANCER RESEARCH, 2019, 8 (06) : 2223 - 2229
  • [8] EGFR-TKI rechallenged treatment combined with apatinib in non-small cell lung cancer with EGFR-TKI resistance.
    Liang, Li
    Li, Fang
    Cao, Baoshan
    Zhang, Zhaohui
    Zhu, Xiang
    Wang, Jiadong
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [9] Efficacy and safety of apatinib plus EGFR-TKI in advanced non-small cell lung cancer with EGFR-TKI resistance
    Tian, R.
    ANNALS OF ONCOLOGY, 2021, 32 : S980 - S981
  • [10] Immunotherapy-based regimens for patients with EGFR-mutated non-small cell lung cancer who progressed on EGFR-TKI therapy
    Qin, Bao-Dong
    Jiao, Xiao-Dong
    Yuan, Ling-Yan
    Wu, Ying
    Ling, Yan
    Zang, Yuan-Sheng
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2024, 12 (04)
12345